About this trial
The introduction of combination antiretroviral therapy (cART) has completely revolutionized the management of HIV-positive patients, drastically reducing HIV-associated mortality and morbidity. In fact, the course of HIV infection has transformed into a chronic disease. The availability of different classes of antiretroviral drugs, such as nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), protease inhibitors (PIs), integrase inhibitors (INSTIs) and viral entry inhibitors (IEs) that act in different phases of the HIV life cycle, together with careful patient management, has allowed us to obtain long-lasting therapeutic efficacy in the vast majority of Italian patients, making this infection a chronic disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
signed informed consent
patients treated with triple therapy who simplify to 3TC+DTG
patients treatment-naive who start a dual therapy with 3TC+DTG from clinical practice
Disqualifiers
lack of willingness to provide informed consent
Trial population
HIV subjects treated with Dovato from 2015 to 2022. (retrospective cohort) or who will start treatment from clinical practice with Dovato
Trial design
Cohort
Other
Treatments tested in this trial
Blood sampling for evaluation of biomarkers
Other interventionNon-routine diagnostic test evaluations
Treatment groups
Trial outcomes
Primary outcomes
Establishment of a database
Systematic and continuous collection of data related to clinical, laboratory and treatment characteristics of patients who simplify from triple standard ART or who continue dual therapy with 3TC+DTG, or treatment-naive patients who start the dual regimen with 3TC+DTG. The data will be useful for the evaluation of diagnostic and multiparametric algorithms.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: